Momefusid

Momefusid (LAS41003) is a fixed-dose combination topical therapy developed by Almirall, S.A., containing the potent synthetic corticosteroid mometasone furoate (0.1%) and the narrow-spectrum antibiotic fusidic acid (2%). It is specifically indicated for the treatment of inflammatory skin disorders, such as super-infected eczema (atopic dermatitis), where a secondary bacterial infection—most commonly caused by *Staphylococcus aureus*—is present or suspected. Mometasone furoate provides anti-inflammatory, antipruritic, and vasoconstrictive effects by acting as an agonist at the glucocorticoid receptor, thereby modulating the expression of genes involved in the inflammatory response. Fusidic acid provides antimicrobial activity by inhibiting bacterial protein synthesis through interference with elongation factor G (EF-G), which prevents the translocation of the ribosome along the mRNA. This dual-action approach allows for the simultaneous management of both the underlying allergic inflammation and the complicating bacterial load.

Brand names

Momefusid

Other names

mometasone furoate + fusidic acid